(MedPage Today) — CHICAGO — Semaglutide further solidified its efficacy for diabetes-associated cardiovascular conditions, this time building its positions in peripheral artery disease (PAD) and with an oral formulation, based on two major…
Source link : https://www.medpagetoday.com/meetingcoverage/acc/114883
Author :
Publish date : 2025-03-29 18:30:00
Copyright for syndicated content belongs to the linked Source.
